{"nctId":"NCT02373371","briefTitle":"Actinic Keratoses Treatment With Metvix速 in Combination With Light","startDateStruct":{"date":"2015-03-25","type":"ACTUAL"},"conditions":["Actinic Keratoses"],"count":26,"armGroups":[{"label":"Daylight","type":"EXPERIMENTAL","interventionNames":["Drug: Metvix速","Procedure: Photodynamic Therapy Daylight"]},{"label":"Conventional treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Metvix速","Procedure: Photodynamic Therapy Blue light"]}],"interventions":[{"name":"Metvix速","otherNames":[]},{"name":"Photodynamic Therapy Blue light","otherNames":[]},{"name":"Photodynamic Therapy Daylight","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female above 18 years;\n* Subject with clinical diagnosis of mild Actinic Keratosis (AK) on the face or the scalp with or without clinical diagnosis of moderate AK on the target areas (TAs);\n\nExclusion Criteria:\n\n* Subject with clinical diagnosis of at least one severe AK on TAs\n* Subject with clinical diagnosis of other skin disease (including non-melanoma skin cancer) on the TAs;\n* Subject with pigmented AK on the TAs","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Total Number of Treated Mild Lesions Per Side at Week 12","description":"The number of lesions is assessed at baseline (before treatment) and 12 weeks later.\n\nThe difference in lesions is recorded for each patient. The mean of disappeared lesions are then calculated for all patients.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"6.0"},{"groupId":"OG001","value":"20.0","spread":"6.9"}]}]}]},{"type":"SECONDARY","title":"Pain Assesment","description":"Pain assesment with a VAS Pain scale\n\nVisual analog scale \\[VAS\\] is a continuous scale comprised of a horizontal scale of 10 cm length . The scale is anchored by \"no pain\" (score of 0) and \"pain as bad as it could be\" or \"worst imaginable pain\" (score of 10).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.9"},{"groupId":"OG001","value":"5.1","spread":"2.1"}]}]}]},{"type":"SECONDARY","title":"Lesions Disappearance Rate at 1 Months From Baseline.","description":"The number of lesions is assessed at baseline (before treatment) and 1 month later.\n\nThe difference in lesions is recorded for each patient. The rate is the quotient: \" difference in lesions between baseline and at 1 month \"/nubmer of lesions at baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.6","spread":"7.2"},{"groupId":"OG001","value":"94.6","spread":"4.8"}]}]}]},{"type":"SECONDARY","title":"Lesions Disappearance Rate at 6 Months From Baseline.","description":"The number of lesions is assessed at baseline (before treatment) and 6 month later.\n\nThe difference in lesions is recorded for each patient. The rate is the quotient: \" difference in lesions between baseline and at 6 month \"/nubmer of lesions at baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.9","spread":"5.9"},{"groupId":"OG001","value":"94.7","spread":"5.4"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":13},"commonTop":[]}}}